Lungs News and Research

RSS

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Pfizer Inc. announced today the discontinuation of the SUN 1170 Phase 3 open-label study of Sutent(r) (sunitinib malate) in advanced hepatocellular carcinoma, or liver cancer. Following a review by the independent Data Monitoring Committee, the study was discontinued based on a higher incidence of serious adverse events in the sunitinib arm compared to the sorafenib arm and the fact that sunitinib did not meet the criteria to demonstrate that it was either superior or non-inferior to sorafenib in the survival of patients with advanced hepatocellular cancer.

23 Apr 2010

Cancers deficient in ASS enzyme allow ADI-PEG 20 to inhibit cancer cell growth

Polaris Group scientists and university collaborators reported at the American Association for Cancer Research (AACR), that a number of different cancers have a deficiency in a specific enzyme, argininosuccinate synthetase (ASS), which allows pegylated arginine deiminase (ADI-PEG 20) to inhibit cancer cell growth.

22 Apr 2010

IL-10 Gene Therapy helps repair damaged lungs found unfit for transplant

Promising research brings hope for the almost two thousand lung transplant candidates who currently make up The United Network for Organ Sharing's (UNOS) wait list. A new technique that uses gene therapy to help repair damaged lungs previously found unfit for transplant shows promise for addressing the critical shortage of healthy donor organs.

22 Apr 2010

ISHLT announces new guidelines for heart transplant recipients

The International Society for Heart and Lung Transplantation (ISHLT) today announces new guidelines to standardize care for heart transplant patients worldwide. The guidelines demonstrate a united effort to decrease complications, improve outcomes and increase patient survival rates among heart transplant recipients. The guidelines will be presented during today's symposium The ISHLT Guidelines for Heart Transplant Recipients: Towards an International Consensus at the ISHLT 30th Annual Meeting and Scientific Sessions at the Hilton Chicago.

22 Apr 2010

Immunomedics reports on ribonuclease-based immunotoxin development at AACR meeting

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported results from two studies on the development of ribonuclease-based immunotoxins at the American Association for Cancer Research conference.

22 Apr 2010

Positive results from preclinical EP-302 program presented at AACR 2010

Drug discovery and development company Esperance Pharmaceuticals today presented positive results from their preclinical EP-302 program that support the initiation of IND enabling studies. EP-302 is a targeted membrane-disrupting peptide designed to selectively kill cells that express nucleolin on their surface. Nucleolin is a protein that is over-expressed in a wide range of cancers and tumor endothelial cells.

22 Apr 2010

Hereditary ovarian cancer patients may develop secondary tumours in liver and spleen

Scientists have taken a major step forward in the understanding of ovarian cancer, which could improve treatment for patients with the condition.

22 Apr 2010

PharmaMar presents new trials with Yondelis, Zalypsis and Irvalec anti-tumor drugs at 101st AACR meeting

PharmaMar, a biopharmaceutical company owned by Grupo Zeltia (ZEL.MC), presented six new trials with marine-based anti-tumor drugs Yondelis(R), Zalypsis(R) and Irvalec(R) at the American Association for Cancer Research's (AACR) 101st Annual Meeting, held in Washington, D.C. from April 17-21.

22 Apr 2010

Medical technology innovation strives for personal focus, cost-efficiency

Medtronic CEO Bill Hawkins says the products made by his company, like pacemakers, insulin pumps and neurostimulators are the "ultimate personal technologies," according to CNNMoney. He said a shift in his industry is moving towards health information technology that people will depend on and use with their cell phones and laptops.

22 Apr 2010

Penn State researchers to test education program on patients with high blood pressure

When it comes to chronic diseases, knowledge is power, according to Penn State researchers who will test an education program on patients with high blood pressure to help them manage their disease.

22 Apr 2010

Genmab introduces new pre-clinical antibody program and novel bispecific antibody technology

Genmab A/S will announce today at its Annual General Meeting a new pre-clinical antibody program, HuMax-cMet,as well as a novel next generation bispecific antibody technology.

22 Apr 2010

Children born very early have abnormal lung function: U.K. researchers

More than half of children who were born very early—at 25 weeks or less (normal gestation is around 40 weeks)— have abnormal lung function and are twice as likely as their full-term peers to have a diagnosis of asthma, according to U.K. researchers, who followed a national cohort of extremely preterm infants to age 11.

22 Apr 2010

LIJ Medical Center to acquire TrueBeam system for cancer treatment

In a promising development for cancer patients in the New York metropolitan area, the Long Island Jewish (LIJ) Medical Center Department of Radiation Medicine announced today that it will acquire an innovative new system called TrueBeam that offers a radically different approach to treating cancer with image-guided radiotherapy.

22 Apr 2010

Early tracheotomy does not reduce risk of VAP in mechanically ventilated adult ICU patients

Adult ICU patients who received tracheotomy 6 to 8 days vs. 13 to 15 days after mechanical ventilation did not have a significant reduction in the risk of ventilator-associated pneumonia, according to a study in the April 21 issue of JAMA.

21 Apr 2010

Clarient Insight Dx Pulmotax assay helps predict response to chemotherapy in lung cancer patients

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that data from a new study suggest that the Clarient Insight® Dx Pulmotax™ assay may effectively predict which lung cancer patients will respond favorably to chemotherapy. The study, titled "TLE3 expression is predictive of response to chemotherapy in NSCLC," included 368 samples from carcinoma patients.

21 Apr 2010

MicroRNAs control levels of Myc protein in Drosophila: Researchers

In all cancers, whether in kidney, breast, lung, colon, skin or any other tissue, cells show high Myc protein levels. Excess Myc causes cells to multiply in an exaggerated manner, giving rise to the development of tumours. One of the most pressing questions about Myc is how healthy cells keep the expression of this protein in check.

21 Apr 2010

Initial results of gallium-containing compound to treat serious infection presented at AACR 2010

Genta Incorporated today announced the presentation of initial results from the first human use of a gallium-containing compound to treat serious infection. In a patient with cystic fibrosis and a highly resistant lung infection, who has been treated over a 2-year period, high concentrations of gallium were achieved in sputum.

21 Apr 2010

ARIAD presents AP26113 investigational ALK inhibitor preclinical study data at AACR annual meeting

ARIAD Pharmaceuticals, Inc. today announced results of preclinical studies on its investigational anaplastic lymphoma kinase (ALK) inhibitor - AP26113 - showing potent inhibition of the target protein and of mutant forms that are resistant to the first-generation ALK inhibitor, which currently is in clinical trials in patients with cancer. ARIAD scientists presented these data today at the annual meeting of the American Association for Cancer Research (AACR) in Washington, D.C.

21 Apr 2010

Immunomedics reports study results of antibody-SN-38 conjugates for targeted cancer chemotherapy

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, reported today at the 101st Annual Meeting of the American Association for Cancer Research (AACR) results from two studies aimed at improving the design of antibody-SN-38 conjugates for targeted cancer chemotherapy.

21 Apr 2010

Plexxikon presents promising preclinical data from PLX3397 in vivo cancer studies

Plexxikon Inc. today announced promising preclinical data from in vivo cancer studies with PLX3397 demonstrating significant reduction in tumor burden, metastatic spread, bone erosion and cancer bone pain. PLX3397 is an oral, selective kinase inhibitor that down-modulates macrophages, microglia, osteoclasts and mast cells, all cell types targeted by this drug candidate. These cell types play a key role in cancer and metastasis.

21 Apr 2010

Lungs News and Research

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Cancers deficient in ASS enzyme allow ADI-PEG 20 to inhibit cancer cell growth

IL-10 Gene Therapy helps repair damaged lungs found unfit for transplant

ISHLT announces new guidelines for heart transplant recipients

Immunomedics reports on ribonuclease-based immunotoxin development at AACR meeting

Positive results from preclinical EP-302 program presented at AACR 2010

Hereditary ovarian cancer patients may develop secondary tumours in liver and spleen

PharmaMar presents new trials with Yondelis, Zalypsis and Irvalec anti-tumor drugs at 101st AACR meeting

Medical technology innovation strives for personal focus, cost-efficiency

Penn State researchers to test education program on patients with high blood pressure

Genmab introduces new pre-clinical antibody program and novel bispecific antibody technology

Children born very early have abnormal lung function: U.K. researchers

LIJ Medical Center to acquire TrueBeam system for cancer treatment

Early tracheotomy does not reduce risk of VAP in mechanically ventilated adult ICU patients

Clarient Insight Dx Pulmotax assay helps predict response to chemotherapy in lung cancer patients

MicroRNAs control levels of Myc protein in Drosophila: Researchers

Initial results of gallium-containing compound to treat serious infection presented at AACR 2010

ARIAD presents AP26113 investigational ALK inhibitor preclinical study data at AACR annual meeting

Immunomedics reports study results of antibody-SN-38 conjugates for targeted cancer chemotherapy

Plexxikon presents promising preclinical data from PLX3397 in vivo cancer studies

The ultimate guide to lung research tools and protocols eBook

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Latest News